IMUNON’s Post

We are dedicated to transforming care for women facing advanced ovarian #cancer. Additional insights from our Phase 2 OVATION 2 study highlight the potential of our proprietary TheraPlas® technology to address the urgent need for new treatment options. With plans underway to initiate a Phase 3 pivotal clinical trial in early 2025, we remain focused on advancing innovation to make a meaningful difference for patients and their families. Read more in our press release: https://lnkd.in/e4M6uvgA

  • graphical user interface, application, Teams

To view or add a comment, sign in

Explore topics